Objective To assess the efficacy and safety of prophylactic alpha-interfection therapy in liver allograft recipients. Patients An open-label consecutive series of liver transplant recipients who underwent surgery for chronic hepatitis B virus (HBV) and C virus (HCVJ disease. Interventions: Alpha-interferon, 5MU three times weekly, was administered to 16 liver allograft recipients, beginning 3 weeks after transplantation for a total of 6 months or more. Main outcome measures Clearance of hepatitis B surface antigen (HBsAg) or HCV-RNA from blood, liver histology and standard measures of liver biochemistry. Results Of the patients with HBV-related disease, seven out of eight remained HBsAg-negative despite discontinuing anti-HBV hyperimmune gammaglobulim therapy. None of the patients with HCV disease became HCV-RNA-negative. All experienced progression in their hepatitis activity index (Knodell) score. Only two episodes of liver allograft rejection were observed, both of which were easily treated with additional immunosuppression. Conclusions Prophylactic interferon therapy can be administered to liver allograft recipients for the prevention of recurrent HBV infection. At a dose of 5MU three times weekly, alpha-interferon enhanced HBsAg clearance, but failed to clear HCV-RNA.

Gurakar, A., Fagiuoli, S., Hassanein, T., Kingery, L., Wright, H., Ersoz, S., et al. (1994). Prophylactic alpha-interferon therapy following liver transplantation: does it prevent allograft infection?. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 6(5), 429-432.

Prophylactic alpha-interferon therapy following liver transplantation: does it prevent allograft infection?

FAGIUOLI S;
1994

Abstract

Objective To assess the efficacy and safety of prophylactic alpha-interfection therapy in liver allograft recipients. Patients An open-label consecutive series of liver transplant recipients who underwent surgery for chronic hepatitis B virus (HBV) and C virus (HCVJ disease. Interventions: Alpha-interferon, 5MU three times weekly, was administered to 16 liver allograft recipients, beginning 3 weeks after transplantation for a total of 6 months or more. Main outcome measures Clearance of hepatitis B surface antigen (HBsAg) or HCV-RNA from blood, liver histology and standard measures of liver biochemistry. Results Of the patients with HBV-related disease, seven out of eight remained HBsAg-negative despite discontinuing anti-HBV hyperimmune gammaglobulim therapy. None of the patients with HCV disease became HCV-RNA-negative. All experienced progression in their hepatitis activity index (Knodell) score. Only two episodes of liver allograft rejection were observed, both of which were easily treated with additional immunosuppression. Conclusions Prophylactic interferon therapy can be administered to liver allograft recipients for the prevention of recurrent HBV infection. At a dose of 5MU three times weekly, alpha-interferon enhanced HBsAg clearance, but failed to clear HCV-RNA.
Articolo in rivista - Articolo scientifico
Alpha-interferon; Hepatitis C virus RNA; Liver allograft;
English
429
432
4
Gurakar, A., Fagiuoli, S., Hassanein, T., Kingery, L., Wright, H., Ersoz, S., et al. (1994). Prophylactic alpha-interferon therapy following liver transplantation: does it prevent allograft infection?. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 6(5), 429-432.
Gurakar, A; Fagiuoli, S; Hassanein, T; Kingery, L; Wright, H; Ersoz, S; Caraceni, P; Gavaler, J; Van Thiel, D
File in questo prodotto:
File Dimensione Formato  
GURAKAR EJGH 1994 p. 429.pdf

Solo gestori archivio

Dimensione 317.91 kB
Formato Adobe PDF
317.91 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/353260
Citazioni
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
Social impact